Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1795393 | 1.00 | FFAR1 (0.54) | FFAR1EPHX2P2RY14TMEM97IDO1 | |
| SCHEMBL1474431 | 1.00 | FFAR1 (0.54) | FFAR1EPHX2P2RY14TMEM97IDO1 | |
| SCHEMBL23425321 | 1.00 | FFAR1 (0.54) | FFAR1EPHX2P2RY14TMEM97IDO1 | |
| SCHEMBL1474653 | 1.00 | FFAR1 (0.54) | FFAR1EPHX2P2RY14TMEM97IDO1 | |
| SCHEMBL19403737 | 0.84 | HTR2C (0.46) | FFAR1HTR2CCNR1KCNH2 | |
| SCHEMBL23550026 | 0.84 | HTR2C (0.46) | FFAR1HTR2CCNR1KCNH2 | |
| SCHEMBL22398100 | 0.84 | FFAR1 (0.53) | FFAR1P2RY14TMEM97HTR2CCNR1 | |
| SCHEMBL23550049 | 0.84 | HTR2C (0.46) | FFAR1HTR2CCNR1KCNH2 | |
| SCHEMBL19403677 | 0.84 | HTR2C (0.46) | FFAR1HTR2CCNR1KCNH2 | |
| SCHEMBL1474216 | 0.83 | FFAR1 (0.50) | FFAR1EPHX2P2RY14TMEM97IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112312902-B | Pd (II) -catalyzed enantioselective C-H arylation of free carboxylic acids | 斯克里普斯研究学院 | 2022-02-18 | — | — | CN | disclosed |
| US-11021427-B2 | Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021427-B2 | Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210087131-A1 | PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE | 2021-03-25 | — | — | US | disclosed |
| US-20210087131-A1 | PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE | 2021-03-25 | — | — | US | disclosed |
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| US-7951829-B2 | Benzimidazole modulators of VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-31 | — | — | US | disclosed |
| EP-2021330-B1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-22 | — | — | EP | disclosed |
| EP-2021330-A2 | BENZIMIDAZOLE MODULATORS OF VR1 | Janssen Pharmaceutica, N.V. (BE) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007130780-A2 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | FFAR1 578/4885EPHX2 4744/4885P2RY14 392/4885 |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | VRK1, VRK2, VIL1 | FFAR1 578/4885EPHX2 4744/4885P2RY14 392/4885 |
| US-11021427-B2 | Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids | PDCD1, PDK3, PDCD1LG2 | FFAR1 119/4885EPHX2 314/4885P2RY14 4548/4885 |
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | FFAR1 578/4885EPHX2 4744/4885P2RY14 392/4885 |
| US-20210087131-A1 | PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS | PDCD1, PDK3, PDCD1LG2 | FFAR1 124/4885EPHX2 291/4885P2RY14 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.